Research graph
References from Meningococcal meningitis in patients under prolonged eculizumab therapy: Clinical and immunological observations from a case series. Local targets link to admitted publications; unresolved targets remain external evidence.
Atypical hemolytic uremic syndrome: diagnosis, management, and discontinuation of therapy
10.1182/hematology.2024000543 · 2024 · External reference
The role of the complement system in the pathogenesis of infectious forms of hemolytic uremic syndrome
10.3390/biom14010039 · 2023 · External reference
Atypical hemolytic–uremic syndrome: genetic basis, clinical manifestations, and a multidisciplinary approach to management
10.2147/jmdh.s245620 · 2023 · External reference
Current landscape of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitors and regulators
10.1177/20406207241307500 · 2024 · External reference
Thrombosis in paroxysmal nocturnal hemoglobinuria (PNH): from pathogenesis to treatment
10.3390/ijms252212104 · 2024 · External reference
The path to accessible care: development and impact of eculizumab biosimilars for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome
10.1007/s40259-025-00707-3 · 2025 · External reference
Rituximab and eculizumab when treating nonmalignant hematologic disorders: infection risk, immunization recommendations, and antimicrobial prophylaxis needs
10.1182/hematology.2020000171 · 2020 · External reference
High risk for invasive meningococcal disease among patients receiving eculizumab (soliris) despite receipt of meningococcal vaccine
10.15585/mmwr.mm6627e1 · 2017 · External reference
Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab
10.1007/s00277-017-2924-y · 2017 · External reference
Failure of first meningococcal vaccination in patients with atypical haemolytic uraemic syndrome treated with eculizumab
10.1093/ndt/gfy225 · 2020 · External reference
10.1016/j.cmi.2018.02.002
10.1016/j.cmi.2018.02.002 · 2018 · External reference
The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations
10.1080/14760584.2019.1557520 · 2019 · External reference
Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults
10.1182/blood-2017-05-781450 · 2017 · External reference
Antibiotic prophylaxis in vaccinated eculizumab recipients who developed meningococcal disease
10.1016/j.jinf.2019.11.015 · 2020 · External reference
Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trial
2024 · External reference
Randomized trial showing persistence of hSBA titers elicited by a pentavalent meningococcal MenABCWY vaccine for up to 4 years following a primary series and safety and immunogenicity of a booster dose
10.1016/j.vaccine.2024.126469 · 2025 · External reference
Case report: benefits and challenges of long-term eculizumab in atypical hemolytic uremic syndrome
10.1542/peds.2014-3503 · 2015 · External reference
A rare case of septic shock due to Neisseria meningitidis serogroup B infection despite prior vaccination in a young adult with paroxysmal nocturnal haemoglobinuria receiving eculizumab
10.1016/j.vaccine.2018.03.087 · 2018 · External reference
Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis
10.1097/qco.0000000000000279 · 2016 · External reference
Preventing infectious complications when treating non-malignant immune-mediated hematologic disorders
10.1002/ajh.25642 · 2019 · External reference
